SavedAdd your journal

Journals / Turkish Journal of Biology / 2017 / Cilt: 41 - Sayı: 6

Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells

Buket KOSOVA
Asu Fergün YILMAZ
Burçin KAYMAZ
Filiz VURAL
Fahri ŞAHİN
Çağdaş AKTAN
Güray SAYDAM
Melda CÖMERT
Nur SOYER
Ajda GÜNEŞ
Pages
926–934
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The data obtained could lead to determining new therapeutic targetsfor CML patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the era of tyrosine kinase inhibitors, resistance still constitutes a problem in chronic myeloid leukemia (CML) patients;thus, new pathway-specific inhibitors like miRNAs have become important in the treatment of refractory patients.
📊
Key Findings & Data:There are nosatisfying data regarding the miRNAs and anti-miRNA treatment targeting STAT5A and 5B.
💡
Conclusion & Impact:The data obtained could lead to determining new therapeutic targetsfor CML patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In the era of tyrosine kinase inhibitors, resistance still constitutes a problem in chronic myeloid leukemia (CML) patients;thus, new pathway-specific inhibitors like miRNAs have become important in the treatment of refractory patients. There are nosatisfying data regarding the miRNAs and anti-miRNA treatment targeting STAT5A and 5B. In this study, we first researched the effectof dasatinib on apoptosis in the CML cell line K562. The expressions of miRNAs possibly targeting both STAT5A and 5B were thendetermined. The down- and upregulation of the miRNAs were compared using the ΔΔCT method. At the last stage of the study, we useda new primer probe in order to validate the results. The level of hsa-miR-940 was decreased 4.4 times and the levels of hsa-miR-527 andhsa-miR-518a-5p were increased 12.1 and 8 times, respectively, in the dasatinib-treated group when compared to the control group.We detected similar results in the validation step. As a conclusion, we determined the expression profiles of miRNAs targeting STAT5Aand 5B that had an important role in the pathogenesis of CML. The data obtained could lead to determining new therapeutic targetsfor CML patients.

🔖

Cite This Article

KOSOVA, B., YILMAZ, A. F., KAYMAZ, B., VURAL, F., ŞAHİN, F., AKTAN, Ç., SAYDAM, G., CÖMERT, M., SOYER, N., GÜNEŞ, A. (2022). Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells. Turkish Journal of Biology, Cilt: 41 - Sayı: 6, 926–934. https://ajindex.com/articles/600329

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A et al. (2008). Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 6: 1830-1840.
  2. Apperley JF (2007). Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029.
  3. Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ (2014). Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer 31: 14-51.
  4. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
  5. Benekli M, Baumann H, Wetzler M (2009). Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27: 4422-4432.
  6. Bowman T, Garcia R, Turkson J, Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488.
  7. Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M (2008). Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506.
  8. Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
  9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K et al. (2002), Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. P Natl Acad Sci USA 99: 15524-15529.
  10. Cheng AM, Byrom MW, Shelton J, Ford LP (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297.
  11. Dalgiç CT, Kaymaz BT, Dalmizrak A, Cömert Özkan M, Kosova B, Şahin F, Saydam G (2015). Investigating the role of JAK/STAT pathway on dasatinib-induced apoptosis for CML cell model K562. Clin Lymphoma Myeloma Leuk 15: 161-166.
  12. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, Lister TA, Young BD, Debernardi S (2008). Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3: e2141. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ et al. (2010). miR- 328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140: 652-665.
  13. Farazi TA, Spitzer JI, Morozov P, Tusch